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Abstract Perfusion and diffusion magnetic resonance
imaging (pMRI, dMRI) are valuable diagnostic tools for
assessing brain tumors in the clinical setting. The aim of
this study was to determine the correlation of pMRI and
dMRI with 11C-methionine positron emission tomography
(MET PET) in suspected low-grade gliomas (LGG) prior to
surgery. Twenty-four adults with suspected LGG were
enrolled in an observational study and examined by MET
PET, pMRI and dMRI. Histological tumor diagnosis was
confirmed in 23/24 patients (18 gliomas grade II, 5 gliomas
grade III). The maximum relative cerebral blood volume
(rCBVmax) and the minimum mean diffusivity (MDmin)
were measured in tumor areas with highest MET uptake
(hotspot) on PET by using automated co-registration of
MRI and PET scans. A clearly defined hotspot on PET was
present in all 23 tumors. Regions with rCBVmax corre-
sponded with hotspot regions in all tumors, regions with
MDmin corresponded with hotspot regions in 20/23 tumors.
The correlation between rCBVmax (r = 0.19, P = 0.38)
and MDmin (r = -0.41, P = 0.053) with MET uptake in
the hotspot was not statistically significant. Taken into
account the difficulties of measuring perfusion abnormali-
ties in non-enhancing gliomas, this study demonstrates that
co-registered MET PET and pMRI facilitates the identifi-
cation of regions with rCBVmax. Furthermore, the lack of a
clear positive correlation between tumor metabolism in
terms of MET uptake and tumor vascularity measured as
rCBVmax suggests that combined pMRI/PET provides
complementary baseline imaging data in these tumors.
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Introduction
Low-grade gliomas (LGG) in adults refer to a heteroge-
neous group of primary brain tumors classified as astro-
cytomas, oligodendrogliomas, and oligoastrocytomas
World Health Organization (WHO) grade II [1]. LGG grow
slowly and patients have a highly variable prognosis
depending on clinical prognostic factors as well as specific
histological and molecular tumor characteristics [2].
However, most if not all LGG progress to high-grade gli-
omas (HGG) with eventually fatal outcome.
The optimal timing of treatment for LGG remains
controversial [3]. A particular challenge is the interpreta-
tion of stable disease. From a radiological point of view,
there is no stable disease. LGG expand continuously during
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the clinically stable phase of disease, with a radiological
mean growth rate of *4 mm/year before malignant
transformation [4]. Already during the initial ‘‘silent’’
period when these tumors may be discovered incidentally,
there is a continuous growth at a rate similar to that during
later phases [5]. The symptomatic phase is usually initiated
by new-onset seizures, occurring in 70–90 % of all patients
[6]. Focal neurologic deficits as initial symptoms are less
common, probably related to the slow tumor growth,
allowing functional compensation through brain plasticity
mechanisms [7].
Taking into account the slow but continuous growth of
LGG, early surgical resection is recommended for patients
with operable tumors [7]. For patients with inoperable
tumors or tumors in eloquent areas, a ‘‘watchful waiting’’
strategy with regular clinical and imaging surveillance may
be adopted. These patients will be subjected to diagnostic
biopsy and adjuvant radio- and/or chemotherapy when
signs of more aggressive tumor growth occur. Thus, there
is a need for sensitive imaging techniques to identify
patients at risk for early tumor progression amongst sus-
pected LGG.
Morphological MRI shows anatomical tumor location,
tumor size, and contrast enhancement at presentation and is
used to determine the individual tumor growth rate by
repeated volumetric measurements over time [8]. Physio-
logical MRI such as perfusion (pMRI) and diffusion
(dMRI) imaging provide additional information on tumor
vascularity and cellularity [9–11]. To date, perfusion and
diffusion parameters are no reliable preoperative predictors
of tumor grade in suspected LGG due to overlapping val-
ues between tumors with different tumor grades and his-
tological subtypes [12]. However, these methods have
become valuable diagnostic tools for LGG in the clinical
setting.
Positron emission tomography (PET) with the tracer
11C-methionine (MET) is another valuable method in the
clinical management of LGG that allows evaluation of
metabolic tumor activity [13, 14]. The uptake of the amino
acid tracer MET is up-regulated in glioma capillaries [15]
and correlates with increased cell proliferation and tumor
malignancy grade [16]. MET accumulates markedly in
malignant gliomas but accumulates also in the absence of
contrast enhancement [17, 18]. MET PET is used to dif-
ferentiate between neoplastic and non-neoplastic lesions,
for stereotactic biopsies guidance [19], and as a prognostic
marker for LGG [20]. For these purposes, MET PET is
performed as part of the preoperative diagnostic work-up at
our hospital in all suspected LGG.
In this observational study, we investigated a series of
24 adults presenting with suspected LGG by pMRI and
dMRI, in addition to MET PET. The study design was set
to reflect the clinical situation at our center where decisions
by the neuro-oncology team are based on clinical param-
eters, morphological MRI and MET PET. Our aim was to
study the correlation of pMRI and dMRI with MET PET in
this population prior to histopathological diagnosis.
Materials and methods
Patient population
Twenty-four patients ([18 year) presenting with suspected
LGG referred to the Neurosurgery Department, Uppsala
University Hospital, between February 2010 and Septem-
ber 2012 were enrolled and investigated by morphological
MRI, pMRI and dMRI according to the study protocol. The
institutional review board approved the study and written
informed consent was obtained prior to participation.
Inclusion criteria were clinical and morphological MRI
findings suggestive of LGG, and a maximum time interval
between PET and MRI of 90 days. Radiological diagnosis
was based on typical appearance on morphological MRI
with T1-weighted MRI showing no or minimal contrast
enhancement. Clinical exclusion criteria were the presence
of major neurological or cognitive deficits suggestive of
HGG. MET PET findings were incorporated in clinical
decisions to obtain early histology-proven diagnosis but
high MET uptake suggestive of HGG did not exclude
patients from the study [14].
MRI techniques
Morphological MRI sequences with a 3T scanner (Philips
Achieva, Best, the Netherlands) included sagittal and axial
T2-weighted turbo spin echo (SE), coronal and axial T2-
weighted fluid attenuated inversion recovery (FLAIR),
axial T1-weighted SE before and after contrast injection,
sagittal T1-weighted 3D turbo field echo after contrast
injection.
pMRI was acquired with a gradient echo echo-planar
imaging (EPI) sequence and dynamic susceptibility con-
trast-enhanced (DSC) technique as previously described
[21]. Relative cerebral blood volume (rCBV) maps were
calculated based on established tracer kinetic models
applied to first pass data using commercial perfusion
analysis software (Nordic Ice, Nordic NeuroLab, Bergen,
Norway) [9, 22, 23].
dMRI was acquired using a SE EPI sequence with the
following scan parameters: TR/TE = 6,700/77 ms; slice
thickness/gap, 2 mm/2 mm, diffusion gradient encoding in
48 directions, b = 1,000 s/mm2. Mean diffusivity (MD)
maps were obtained after automatic pixel-by-pixel calcu-
lation in the scanner as previously described [24].
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PET and MRI images of each case were co-registered
using an automated procedure in a Picture Archiving and
Communication System Carestream (PACS) (Carestream,
Rochester, NY, USA) to ensure precise anatomical com-
parability of MET PET and MRI [25, 26].
MRI analysis
We performed two different sets of perfusion measure-
ments. First, estimations of the average intratumoral per-
fusion were made on rCBV maps only, independently of
MET PET scans. A large circular or oval region of interest
(ROI) was placed in each tumor on the transverse rCBV
map, co-registered with the T2 FLAIR slice with the
largest tumor diameter (mean ROI area 307 mm2), avoid-
ing large blood vessels, cysts, necrosis, and susceptibility
artifacts. The rCBV ratio was calculated by dividing the
mean rCBV in this ROI with the mean rCBV within a ROI
of similar size in the corresponding location of the con-
tralateral hemisphere.
Secondly, perfusion and diffusion measurements were
obtained from co-registered MRI/PET scans. The maxi-
mum relative cerebral blood volume (rCBVmax) and min-
imum mean diffusivity (MDmin) were measured by first
placing a 20 mm2 circular ROI on the rCBV map and on
the MD map in the region corresponding to the PET hot-
spot area. The ROI was then systematically moved outside
the hotspot region in all tumor slices in order to measure
regions with visually suspected high perfusion and low
diffusion, respectively, and to obtain rCBVmax and MDmin
values for each case. The rCBVmax ratio was calculated by
dividing the mean rCBVmax in the tumor ROI by the mean
rCBV in a similar ROI located in normal appearing white
matter of the contralateral hemisphere. MD was also
measured in contralateral white matter in 20 mm2 ROIs to
ensure that measured values were within those of normal
brain tissue.
PET technique
Patients were evaluated prior to treatment that could
interfere with metabolism, except for antiepileptic drugs,
and fasted 4 h before tracer injection. Twelve patients were
examined by ECAT EXACT HR ? camera (Siemens/CTI,
Knoxville) with an axial field of view (FOV) of 15.5 cm,
providing 63 contiguous 2.43 mm slices. In 12 patients, a
Discovery ST (GE Healthcare, Milwaukee) PET/CT scan-
ner was used with a 15.7 cm axial FOV providing 47
contiguous 3.27 mm slices. PET scanning was performed
as described previously [26]. The two PET cameras were
carefully calibrated to ensure interchangeable test results
and stable tracer kinetics in the acquisition time period
[27].
PET analysis
Analysis of PET data was performed using Voyager 4
software (GE Healthcare, Uppsala). ROIs were manually
defined with knowledge of the results of the morphological
MRI. A tumor ROI was drawn around the lesion on the
brain slice containing the five hottest pixels of the lesion
(hotspot). The mean peak pixel value over the five con-
nected pixels, representing an area of about 20 mm2,
defined the maximum MET uptake in the hotspot. To
obtain a tumor-to-normal background ratio, the MET
uptake in the tumor was related to the uptake in a cortical
reference region located in the contralateral hemisphere at
the axial plane of the thalamus [28]. This hotspot/contra-
lateral cortex ratio (HS/cortex ratio) was used for all sta-
tistical analyses. In case of heterogeneously enhanced MET
uptake in the tumor, multiple hotspots were delineated
separately and the highest HS/cortex ratio was used.
Histopathology
Histological diagnosis was obtained by resection (n = 17)
or biopsy (n = 7). All biopsies were directed to MET
hotspot regions, except for one patient with a hotspot in the
primary motor cortex. In this case, biopsy was derived
from the region adjacent to the hotspot region. The neu-
ropathologist re-evaluated all clinical diagnoses for the
purpose of the study according to WHO criteria [1]. The
presence of loss of heterozygosity on chromosomal arms
1p and 19q (LOH 1p/19q) in tumors with an oligoden-
droglial component was examined by microsatellite tech-
nique as previously described [29].
Statistical analysis
Analysis of the correlation between rCBVmax, MDmin and
maximum MET uptake in histologically proven tumors
(n = 23) was performed by Spearman correlation test. Dif-
ferences in HS/cortex ratios, rCBVmax and MDmin values
between tumors of different grade and histological subtype
were assessed by non-parametric test (Mann–Whitney). A
P value\0.05 was considered statistically significant. Statisti-
cal analysis was performed using IBM SPSS Inc (version 19).
Results
Patients
Twenty-four patients (12 males, 12 females) with mean age
of 48.9 years (SD ± 15.2, range 22–78 years) at radio-
logical diagnosis were included. Twenty-two patients
(92 %) presented with epileptic seizures and received
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antiepileptic drugs, two patients with minor neurological
symptoms such as dizziness and headache. Clinical, his-
tological and radiological tumor characteristics are sum-
marized in Table 1.
Histological diagnosis
Tumor diagnosis was confirmed in 23 patients (Table 1).
Tumor diagnoses consisted of glioma grade II (n = 18; 8
astrocytomas grade II; 6 oligodendrogliomas grade II; 3 ol-
igoastrocytomas grade II; 1 ganglioglioma grade II) and
glioma grade III (n = 5; 3 astrocytomas grade III; 1 oligo-
dendroglioma grade III; 1 oligoastrocytomas grade III)
(Table 1). Microsatellite analysis confirmed the presence of
LOH 1p/19q in 9/11 tumors (82 %) with an oligodendroglial
component. Patient 5 had biopsies from six different loca-
tions in the tumor-suspected area without histological proof
of tumor and was diagnosed with non-specified encephalitis.
Time interval between PET, MRI, and surgery
The mean time interval between PET and MRI was 9 days
(0–85 days). MET PET was performed on the same day as
MRI (n = 7) or within 1 month from MRI (n = 15). For
two patients, this time interval was 46 respectively
85 days. The mean time interval between completed MRI/
PET imaging and surgery was 70 days (1 day–323 days).
Eleven patients underwent surgery within 4 weeks, eight
patients within 3 months, and five patients within
5–11 months after completed imaging. All five patients
with delayed surgery (5–11 months) showed clinically
stable disease during the entire observation period.
MET PET
All except one patient (23/24) had a clearly defined hotspot
on PET. The majority of cases showed one single hotspot
(n = 17), others two separate hotspots (n = 6) or three
separate hotspots (n = 1). In one tumor without a clear
hotspot (patient 22), the ROI was moved within the tumor
to obtain maximum MET uptake ratios for statistical
analysis. HS/cortex ratios varied from 1.2–3.8 for the
whole sample. The mean HS/cortex ratio for gliomas grade
II (n = 18) was 2.25 ± 0.80 (SD) and for gliomas grade III
(n = 5) 2.52 ± 0.43 (SD).
Morphological MRI
The radiological tumor characteristics of the entire sample
are summarized in Table 1. All lesions had supratentorial
location and involved cortical brain areas. Six tumors
showed minimal contrast enhancement on T1-weighted
images.
Perfusion MRI
The rCBVmax ratios in the PET hotspot and the rCBV ratios
in the large tumor ROI for each case (n = 24) are shown in
Table 1. The mean rCBVmax in PET hotspot regions for the
whole sample was 3.19 ± 1.66 (range 0.92–8.27) (Fig. 1a).
The mean rCBV in the large tumor ROI was 0.99 ± 0.77
(range 0.28–4.24), which was significantly lower
(P = 0.0001). Regions with rCBVmax corresponded to
hotspot regions on PET in all cases. The correlation
between rCBVmax ratios in the hotspot region and HS/
cortex ratios is shown in Fig. 1b (Spearman’s r = 0.19,
Fig. 1 a Box plots showing the distribution of rCBVmax ratios for the
entire sample (n = 24). b Scatter plot showing the correlation
between maximum MET uptake (HS/cortex ratio) and rCBVmax
values in PET hotspot regions in all tumor samples (n = 23). Straight
line, regression line, dotted lined: 95 % CI
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P = 0.38). There was a significant difference in mean
rCBVmax between gliomas grade II and gliomas grade III
(P = 0.04), but not between enhancing and non-enhancing
lesions (P = 0.34).
Diffusion MRI
MDmin values in tumors were equal or higher than in
contralateral normal appearing white matter (data not
shown), in agreement with previous studies [11, 30].
MDmin values in MET hotspot regions varied between 0.65
and 1.9 9 10-3mm2/s (mean 1.0 ± 0.25) (Fig. 2a). In four
lesions, MDmin values were measured in non-hotspot tumor
regions (mean 1.0 ± 0.21 9 10-3 mm2/s; range
0.71–1.17). MDmin values between gliomas grade II and
gliomas grade III were not significantly different
(P = 0.10) (Fig. 2a). The mean MDmin for oligodendrog-
lial tumors harboring LOH 1p/19q (n = 9) was lower than
for those with intact 1p/19q (n = 2), but the difference was
not significant (P = 0.81). Figure 2b shows the correlation
between MDmin values in the hotspot region and HS/cortex
ratios (Spearman’s r = -0.41, P = 0.053).
Discussion
In the present study, we investigated 24 patients with
suspected LGG by morphological MRI, physiological MRI
and MET PET prior to surgery. Our aim was to define the
correlation between MET uptake and perfusion and diffu-
sion abnormalities in these tumors at the time point of
radiological diagnosis. We found that regions with
rCBVmax corresponded with hotspot regions on PET in all
tumors. However, in spite of a consistent topographical
overlap between hotspot on MET PET and areas with
maximum tumor perfusion, there was no significant posi-
tive correlation between rCBVmax and highest MET
uptake. Our results are in contrast to a previous study,
reporting a positive correlation between rCBVmax and
maximum MET uptake and indicating a close link between
amino acid transport in the tumor and vascularity [31]. This
discrepancy may be partly due to the different study pop-
ulations and methodologies, but also to the general diffi-
culties of measuring subtle differences in regional
perfusion in non-enhancing infiltrating tumors [32]. It is
difficult to select a ROI with high intra- and inter-observer
reproducibility in LGG, since perfusion images are noisy
compared to both morphological images and MET PET
scans. Susceptibility artifacts with signal loss and adjacent
signal increase, simulating perfusion increase, may also
disturb perfusion images. In addition, high perfusion values
in vessels and adjacent cortex may be difficult to differ-
entiate from increased tumor perfusion. Therefore, pMRI
alone appears to be unsuited to replace MET PET in pro-
viding reliable baseline data on tumor vascularity. This is
further illustrated by our perfusion measurements calcu-
lated within a large tumor area and without prior knowl-
edge of MET PET, which were significantly lower than the
co-registered PET/MRI measurements. The present study
shows that the co-registered measurement of rCBVmax and
MET uptake is a reliable way to define perfusion abnor-
malities in LGG (illustrated in Fig. 3).
The inclusion criteria for presumed LGG in this study
are in accordance with the traditional imaging view of
these tumors as non- or slightly enhancing tumors. The
absence of contrast enhancement is not specific for LGG,
and the degree of the blood–brain barrier disruption is not
considered diagnostic for either high- or low-grade tumors
Fig. 2 a Box plots showing the distribution of MDmin values for the
entire sample (n = 24). b Scatter plot showing the correlation
between maximum MET uptake (HS/cortex ratio) and MDmin values
(910-3 mm2/s) in PET hotspot regions in all tumor samples
(n = 23). Straight line, regression line, dotted lined: 95 % CI
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[33]. In agreement with previous reports, three non-
enhancing lesions in our study were anaplastic gliomas
while four tumors with minimal contrast enhancement
were LGG [34]. Contrast enhancement is not equivalent
with perfusion abnormality, which reflects the degree of
microvascularization and as such is a better indicator of the
biologic aggressiveness of the tumor [21]. In a retrospec-
tive study of both LGG and HGG, baseline rCBV was a
prognostic predictor for progression-free survival [35].
This is an important observation, indicating that pMRI,
similar to MET PET, can be used to guide timing of
treatment in suspected LGG. Our study suggests that
combined pMRI/PET provides complementary baseline
imaging data on tumor metabolism and vascularity that
could be subsequently used in the follow-up of LGG.
Longitudinal studies of patients with LGG are needed to
determine the specific clinical applications of these meth-
ods as prognostic and/or predictive biomarkers.
HGG usually have higher rCBVmax than LGG, but
rCBVmax may also be elevated in LGG. Oligodendroglial
tumors with their characteristic dense networks of capillary
branches have a generally higher rCBVmax than astrocytic
tumors [12]. The evaluation of rCBV in oligodendroglio-
mas is further complicated by the fact that tumors with co-
deletions of chromosome 1p/19q show generally higher
rCBVmax than non-deleted oligodendrogliomas [36]. In our
relatively small study sample, we found no significant
difference between mean rCBVmax of astrocytic and oli-
godendroglial tumors (data not shown) [37].
We found a negative correlation between MET uptake in
the hotspot and MDmin values, although the correlation did
not reach significance. High MET uptake and restricted
Fig. 3 Patient 8. Preoperative MET PET and MRI of a right-sided
frontal oligodendroglioma grade II in a 31-year-old female. a MET
PET shows the hotspot region of the tumor. b T2-weighted FLAIR
MRI shows a high signal intensity tumor. c T1-weighted contrast-
enhanced MRI shows minimal contrast enhancement in the tumor
area. d DSC perfusion MRI with rCBV color map shows high
perfusion in the tumor area. e DSC perfusion MRI with rCBV grey-
scale map shows high perfusion in the region corresponding to the
PET hotspot. The ROIs in the tumor and in the contralateral normal
appearing white matter are marked. f dMRI where the MDmin value in
the region corresponding to the PET hotspot is lower than MD in the
medial portion of the tumor (but minimally increased compared to
normal appearing contralateral white matter)
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diffusion are both suggestive of more malignant tumor
portions, but a relationship between MET uptake and
MDmin has not been previously reported [10, 11]. Tumor
diffusion as measured by dMRI correlates with tumor cell
density and is decreased in malignant gliomas due to a
higher cellularity with restricted motion of water molecules
in the extracellular space. In spite of generally lower
MDmin values in HGG, dMRI is not useful for preoperative
grading due to the marked overlap in MD values between
gliomas of different histological subtype and grade [30, 38,
39]. Interestingly, a recent report showed that information
on anisotropy provided by diffusion tensor imaging is more
useful than MDmin values for predicting tumor malignancy
[39].
The present study has some limitations apart from the
small sample size. In two patients, the time interval
between PET and MRI investigation exceeded 1 month.
Keeping in mind the continuous growth of LGG, it is
important to perform both imaging studies simultaneously
if possible.
Conclusion
Hotspot regions on MET PET corresponded with maxi-
mum tumor perfusion and mainly low diffusion in non- or
minimal enhancing gliomas. MET PET facilitated the
detection of representative tumor regions with perfusion
abnormalities prior to surgery, and combined pMRI/PET
may provide useful as a baseline investigation in the long-
term follow-up of LGG.
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